Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

By sjmartinez • October 5, 2022

Gaylis NB, Ritter A, Kelly SA, Pourhassan NZ, Tiwary M, Sacha JB, Hansen SG, Recknor C, Yang OO. Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome. Clin Infect Dis. 2022 Sep 30;75(7):1232-1234. doi: 10.1093/cid/ciac226. PMID: 35452519; PMCID: PMC9383814.

Tags: CCR5, immunosuppression, Infectious Diseases, leronlimab, long COVID, Publications

Related Posts

Uptake of the COVID-19 vaccine and its association with vaccine information and misinformation in Malawi

Songo J, Whitehead HS, Phiri K, Kalande P, Lungu E, Phiri S, van Oosterhout J, Moses A, Hoffman RM, Moucheraud C. Uptake of the COVID-19[...]

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

Maertens JA, Thompson GR 3rd, Spec A, Donovan FM, Hammond SP, Bruns AHW, Rahav G, Shoham S, Johnson R, Rijnders B, Schaenman J, Hoenigl M,[...]

Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment

Munroe ES, Grandits GA, Hyzy RC, Prescott HC, Barrett TW, Dewar RL, Engen N, Goodman AL, Hatlen TJ, Highbarger H, Holland TL, Hughes G, Jensen[...]